Safety and Immunogenicity of a novel three-dose recombinant nanoparticle rabies G protein vaccine administered as simulated post exposure immunization: A randomized, comparator controlled, multicenter, phase III clinical study-Reference-Cited by-同舟云学术

Safety and Immunogenicity of a novel three-dose recombinant nanoparticle rabies G protein vaccine administered as simulated post exposure immunization: A randomized, comparator controlled, multicenter, phase III clinical study

Published:2021-09-09 Issue:11 Volume:17 Page:4239-4245
ISSN:2164-5515
Container-title:Human Vaccines & Immunotherapeutics
language:en
Short-container-title:Human Vaccines & Immunotherapeutics

Author:

H S Ravish¹,Khobragade Akash²,Satapathy Durga³,Gupta Monica⁴,Kumar Surendra⁵,Bhomia Vinay⁶,V Ramasubramanian⁷,Desai Maharshi⁸,Agrawal Ashok Dilipkumar⁹^ORCID

Affiliation:

1. Department of Community Medicine, Kempegowda Institute of Medical Science, Bengaluru, India

2. Department of Pharmacology, J J Hospital Byculla, Mumbai, India

3. Department of Community Medicine, VSS Institute of Medical Science and Research, Sambalpur, India

4. Consultant Physician, Samvedna Hospital, Varanasi, India

5. Department of Community Medicine, S P Medical College and A.G Hospitals, Bikaner, India

6. Consultant Physician, Sanjivani Superspeciality Hospital Pvt. Ltd, Ahmedabad, India

7. Senior Consultant, Infectious Diseases and Tropical Medicine, Apollo Hospital, Chennai, India

8. Senior Consultant, Infectious Diseases, Apollo Hospitals International Ltd, Gandhinagar, India

9. Medical Affairs, Cadila Pharmaceuticals Ltd, Ahmedabad, India

Funder

Cadila Pharmaceuticals Ltd., Ahmedabad, India

Publisher

Informa UK Limited

Subject

Pharmacology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/21645515.2021.1957413

Reference36 articles.

1. WHO Expert Consultation on Rabies prevention. Third report. Technical report series no. 1012. Geneva, Switzerland: World Health Organization; 2018.

2. World Health Organization. Rabies Vaccines and Immunoglobulins: WHO position, WHO/CDS/NTD/NZD/2018.04. Geneva, Switzerland: World Health Organization; 2018.

3. Minghui R, Stone M, Semedo MH, Nel L. New global strategic plan to eliminate dog-mediated rabies by 2030. Lancet Glob Health. 2018 Aug;6(8):e828–e829. doi: 10.1016/S2214-109X(18)30302-4. Epub 2018 Jun 18. PMID: 29929890.

4. World Health Organization. Rabies vaccines: WHO position paper – April 2018. Weekly Epidemiological Record, No. 16. 2018;93:201–20.

5. Vaccine Investment Strategy. Global alliance for vaccines and immunization. [accessed 2021 Mar 30] https://www.gavi.org/about/strategy/vaccine-investment-strategy.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Potential option for rabies post-exposure prophylaxis: New vaccine with PIKA adjuvant against diverse Chinese rabies strains;Vaccine;2023-11

2. Rabies in a postpandemic world: resilient reservoirs, redoubtable riposte, recurrent roadblocks, and resolute recidivism;Animal Diseases;2023-05-19

3. Oxygen uptake and transfer rates throughout production of recombinant baculovirus and rabies virus-like particles;Process Biochemistry;2023-01

4. Letter to the editor: Safety and immunogenicity of a novel recombinant rabies vaccine;Human Vaccines & Immunotherapeutics;2022-06-17